# BioMarin Pharmaceutical Inc.

> BioMarin develops, manufactures and sells medicines for rare, genetically defined conditions. Its portfolio spans enzyme therapies for metabolic disorders and Voxzogo for achondroplasia; the 2026 Amicus acquisition added Fabry and Pompe treatments to a business that generated $3.221 billion in 2025 revenue.

- **Founded:** 1997
- **Headquarters:** San Rafael, United States
- **Founders:** Christopher M. Starr (Co-founder; scientist and former Chief Scientific Officer), Grant W. Denison Jr. (Co-founder; biotechnology executive)
- **Products:** Aldurazyme, Naglazyme, Kuvan, Vimizim, Brineura
- **Notable:** First U.S. Aldurazyme approval in 2003 for MPS I., Voxzogo received U.S. approval in 2021; FY2025 revenue reached $927 million., FY2025 total revenue grew 13% to $3.221 billion.

## Products & services

- **Aldurazyme** — Laronidase enzyme replacement for MPS I; manufactured by BioMarin and commercialized globally by Sanofi.
- **Naglazyme** — Galsulfase enzyme replacement for MPS VI.
- **Kuvan** — Sapropterin for responsive phenylketonuria (PKU); now faces generic competition.
- **Vimizim** — Elosulfase alfa enzyme replacement for MPS IVA, also called Morquio A syndrome.
- **Brineura** — Cerliponase alfa enzyme replacement for CLN2 disease, a form of Batten disease.
- **Palynziq** — Pegvaliase enzyme therapy to reduce blood phenylalanine in eligible people with PKU; indications vary by jurisdiction.
- **Voxzogo** — Vosoritide daily injection to increase linear growth in children with achondroplasia and open growth plates; age labels vary by market.
- **Galafold** — Migalastat oral pharmacological chaperone for Fabry disease with amenable variants; acquired with Amicus in 2026.
- **Pombiliti + Opfolda** — Cipaglucosidase alfa plus miglustat for eligible adults with late-onset Pompe disease; acquired with Amicus in 2026.
- **Roctavian** — Historical one-time gene therapy for eligible adults with severe hemophilia A; BioMarin announced voluntary market withdrawal in February 2026.

## Achievements

- First U.S. Aldurazyme approval in 2003 for MPS I.
- Voxzogo received U.S. approval in 2021; FY2025 revenue reached $927 million.
- FY2025 total revenue grew 13% to $3.221 billion.
- Completed Amicus acquisition on April 27, 2026, for approximately $4.8 billion in equity value.
- Current company overview reports nine marketed therapies and approximately 80 countries.

## Latest updates

- **2026-10** — October 9: presented new achondroplasia and hypochondroplasia data at the American Society for Bone and Mineral Research meeting.
- **2026-10** — October 2: presented five-year Pombiliti + Opfolda extension data; an open-label analysis, not a new five-year randomized comparison.
- **2026-09** — September 9: announced publication of positive Phase 3 hypochondroplasia results; this indication remained investigational.
- **2026-09** — September 1: completed Alesta acquisition, adding clinical-stage oral hypophosphatasia candidate ALE1.
- **2026-08** — Second-quarter report recorded $990 million revenue and announced discontinuation of BMN 401 across all indications after ENERGY 3 missed one co-primary endpoint.
- **2026-07** — July 27: announced ReNU syndrome research collaboration with n-Lorem.
- **2026-04** — April 27: completed Amicus acquisition.
- **2026-02** — Announced voluntary withdrawal of Roctavian after failing to identify a qualified buyer; approximately $240 million in related charges recorded in Q4 2025.

## Links

- Website: https://www.biomarin.com/
- LinkedIn: https://www.linkedin.com/company/biomarin/
- Twitter/X: https://twitter.com/BioMarin
- Instagram: https://www.instagram.com/biomarinpharmaceutical/
- Facebook: https://www.facebook.com/BioMarinOfficial

---

Profile page: https://yespress.io/biomarin-pharmaceutical-inc
Published by YesPress — https://yespress.io
Last updated: 2026-10-23